18:08 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Checkpoint's CK-101 leads to 75% ORR in NSCLC subgroup of Phase I/II

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) said twice-daily 400 mg oral CK-101 (RX518) led to an objective response rate (ORR) of 75% in eight treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) in a dose-expansion...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

CK-101: Phase I/II start

Next month, Fortress’ Checkpoint Therapeutics Inc. company will begin an open-label Phase I/II trial of once-daily oral CK-101. The dose-escalation Phase I portion in patients with advanced solid tumors will determine the dose for the...